Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SGUGL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Ispectamab debotansine
|
|||||
| Synonyms |
BMS-986352; CC 99712; SP8919; Anti-BCMA antibody drug conjugate
Click to Show/Hide
|
|||||
| Organization |
Sutro Biopharma, Inc.; Celgene Corp.; Bristol Myers Squibb Co.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
Multiple myeloma [ICD11:2A83]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Ispectamab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Special Approval(s) |
Orphan drug(FDA)
|
|||||
| Puchem SID | ||||||
| ChEBI ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.